Hepatic steatosis with relation to increased expression of peroxisome proliferator-activated receptor-γ in insulin resistant mice

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 4, 2013, Pages 616-623

  Satoh, Hikaru ^a   Ide, Naohito ^a   Kagawa, Yoshiyuki ^a   Maeda, Toshio ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Fat absorption; Hepatic steatosis; Peroxisome proliferator activated receptor

Indexed keywords

CD36 ANTIGEN; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL SIZE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME RELEASE; FATTY ACID OXIDATION; FATTY LIVER; GENE EXPRESSION; INSULIN RESISTANCE; LIPID ABSORPTION; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; LIVER PARENCHYMA; MALE; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN TARGETING; PROTEIN TRANSPORT;

ANIMALS; FATTY LIVER; GENE EXPRESSION; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INTESTINAL ABSORPTION; MALE; MICE; PPAR GAMMA; RNA, MESSENGER; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 84876925898     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-01000     Document Type: Article

References (31)

1. Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. World J. Gastroenterol., 16, 5286-5296 (2010).
2. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment. Pharmacol. Ther., 25, 883-889 (2007).
3. Law K, Brunt EM. Nonalcoholic fatty liver disease. Clin. Liver Dis., 14, 591-604 (2010).
4. Oh MK, Winn J, Poordad F. Review article: diagnosis and treatment of non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther., 28, 503-522 (2008).
5. Yilmaz Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment. Pharmacol. Ther., 36, 815-823 (2012).
6. Burant CF, Sreenan S, Hirano K, Tai TA, Lohmiller J, Lukens J, Davidson NO, Ross S, Graves RA. Troglitazone action is independent of adipose tissue. J. Clin. Invest., 100, 2900-2908 (1997).
7. Chao L, Marcus-Samuels B, Mason MM, Moitra J, Vinson C, Arioglu E, Gavrilova O, Reitman ML. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J. Clin. Invest., 106, 1221-1228 (2000).
8. Memon RA, Tecott LH, Nonogaki K, Beigneux A, Moser AH, Grunfeld C, Feingold KR. Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology, 141, 4021-4031 (2000).
9. Rahimian R, Masih-Khan E, Lo M, van Breemen C, McManus BM, Dubé GP. Hepatic over-expression of peroxisome proliferator activated receptor gamma2 in the ob/ob mouse model of non-insulin dependent diabetes mellitus. Mol. Cell. Biochem., 224, 29-37 (2001).
10. Bedoucha M, Atzpodien E, Boelsterli UA. Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J. Hepatol., 35, 17-23 (2001).
11. Matsusue K, Haluzik M, Lambert G, Yim SH, Gavrilova O, Ward JM, Brewer B Jr, Reitman ML, Gonzalez FJ. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J. Clin. Invest., 111, 737-747 (2003).
12. Morán-Salvador E, López-Parra M, García-Alonso V, Titos E, Martínez-Clemente M, González-Périz A, López-Vicario C, Barak Y, Arroyo V, Clària J. Role for PPARγ in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. FASEB J., 25, 2538-2550 (2011).
13. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, Podevin P, Lacorte JM, Bernhardt C, Bruckert E, Grimaldi A, Poynard T, LIDO Study Group. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) trial. Gastroenterology, 135, 100-110 (2008).
14. Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, Lenaour G, Hartmann-Heurtier A, Bruckert E, Poynard T, LIDO Study Group. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology, 51, 445-453 (2010).
15. Maeda T, Sakita R, Kaihatsu T, Miwa M. Sustained hyperglycemia and insulin resistance induced by dietary restriction. Biol. Pharm. Bull., 24, 950-953 (2001).
16. Noge I, Kagawa Y, Maeda T. A new diabetic mouse model derived from the ddY strain. Biol. Pharm. Bull., 33, 988-992 (2010).
17. Abe C, Ikeda S, Uchida T, Yamashita K, Ichikawa T. Triton WR1339, an inhibitor of lipoprotein lipase, decreases vitamin E concentration in some tissues of rats by inhibiting its transport to liver. J. Nutr., 137, 345-350 (2007).
18. Sasase T, Morinaga H, Yamamoto H, Ogawa N, Matsui K, Miyajima K, Kawai T, Mera Y, Masuyama T, Shinohara M, Ohta T, Matsushita M. Increased fat absorption and impaired fat clearance cause postprandial hypertriglyceridemia in Spontaneously Diabetic Torii rat. Diabetes Res. Clin. Pract., 78, 8-15 (2007).
19. Matsusue K, Kusakabe T, Noguchi T, Takiguchi S, Suzuki T, Yamano S, Gonzalez FJ. Hepatic steatosis in leptin-deficient mice is promoted by the PPARgamma target gene Fsp27. Cell Metab., 7, 302-311 (2008).
20. Ktorza A, Bernard C, Parent V, Penicaud L, Froguel P, Lathrop M, Gauguier D. Are animal models of diabetes relevant to the study of the genetics of non-insulin-dependent diabetes in humans? Diabetes Metab., 23 (Suppl. 2), 38-46 (1997).
21. Greco D, Kotronen A, Westerbacka J, Puig O, Arkkila P, Kiviluoto T, Laitinen S, Kolak M, Fisher RM, Hamsten A, Auvinen P, Yki-Järvinen H. Gene expression in human NAFLD. Am. J. Physiol. Gastrointest. Liver Physiol., 294, G1281-G1287 (2008).
22. Howard BV. Lipoprotein metabolism in diabetes mellitus. J. Lipid Res., 28, 613-628 (1987).
23. Havel PJ, Uriu-Hare JY, Liu T, Stanhope KL, Stern JS, Keen CL, Ahrén B. Marked and rapid decreases of circulating leptin in streptozotocin diabetic rats: reversal by insulin. Am. J. Physiol., 274, R1482-R1491 (1998).
24. Young NL, Saudek CD, Walters L, Lapeyrolerie J, Chang V. Preventing hyperphagia normalizes 3-hydroxy-3-methylglutaryl-CoA reductase activity in small intestine and liver of diabetic rats. J. Lipid Res., 23, 831-838 (1982).
25. Redgrave TG, Snibson DA. Clearance of chylomicron triacylglycerol and cholesteryl ester from the plasma of streptozotocin-induced diabetic and hypercholesterolemic hypothyroid rats. Metabolism, 26, 493-503 (1977).
26. Steiner G, Poapst M, Davidson JK. Production of chylomicron-like lipoproteins from endogenous lipid by the intestine and liver of diabetic dogs. Diabetes, 24, 263-271 (1975).
27. Kageyama H, Hirano T, Okada K, Ebara T, Kageyama A, Murakami T, Shioda S, Adachi M. Lipoprotein lipase mRNA in white adipose tissue but not in skeletal muscle is increased by pioglitazone through PPAR-gamma. Biochem. Biophys. Res. Commun., 305, 22-27 (2003).
28. Hihi AK, Michalik L, Wahli W. PPARs: transcriptional effectors of fatty acids and their derivatives. Cell. Mol. Life Sci., 59, 790-798 (2002).
29. Bocher V, Pineda-Torra I, Fruchart JC, Staels B. PPARs: transcription factors controlling lipid and lipoprotein metabolism. Ann. N. Y. Acad. Sci., 967, 7-18 (2002).
30. Rosen ED, Hsu CH, Wang X, Sakai S, Freeman MW, Gonzalez FJ, Spiegelman BM. C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev., 16, 22-26 (2002).
31. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev., 8, 1224-1234 (1994).